Leaflet: information for the user
Mycophenolate mofetil cinfa 250 mg film-coated tablets
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
The full name of the medication is mycophenolate mofetil cinfa 250 mg film-coated tablets EFG.
Mycophenolate causes congenital malformations and spontaneous abortions.If you are a woman who can become pregnant, you must have a negative pregnancy test result before starting treatment and follow the contraceptive advice provided by your doctor.
Your doctor will explain and provide written information, particularly about the effects of mycophenolate on unborn babies.Read the information carefully and follow the instructions.
If you do not understand these instructions completely, please consult your doctor again before taking mycophenolate.See more information in this section, under the headings “Warnings and Precautions” and “Pregnancy and Breastfeeding”.
Do not take mycophenolate mofetil cinfa
Do not take this medication if you experience any of the above. If you are unsure, consult your doctor or pharmacist before taking mycophenolate mofetil.
Warnings and Precautions
Consult your doctor before starting to take mycophenolate mofetil cinfa
If you experience any of the above (or are unsure), consult your doctor immediately before taking mycophenolate mofetil.
Effect of sunlight
Mycophenolate mofetil reduces your body's defenses. Therefore, there is a greater risk of developing skin cancer. Limit the amount of sunlight and UV light you absorb by:
Other medications and mycophenolate mofetil cinfa
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. This includes over-the-counter medications, including herbal supplements.
This is because mycophenolate mofetil may affect how other medications work. Other medications may also affect how mycophenolate mofetil works.
Specifically, inform your doctor or pharmacist if you are taking any of the following medications before starting mycophenolate mofetil:
Vaccines
If you need to receive a vaccine (live vaccine) during treatment with mycophenolate mofetil, consult your doctor or pharmacist first. Your doctor will advise you on the vaccines you can receive.
You should not donate blood during treatment with mycophenolate mofetil and for at least 6 weeks after completing treatment. Men should not donate semen during treatment with mycophenolate mofetil and for at least 90 days after completing treatment.
Taking mycophenolate mofetil cinfa with food and drinks
The consumption of food and drinks has no effect on your treatment with mycophenolate mofetil.
Pregnancy, breastfeeding, and fertility
Contraception in women taking mycophenolate mofetil cinfa
If you are a woman who can become pregnant, you must use an effective contraceptive method. This includes:
-Before starting to take mycophenolate mofetil cinfa.
-During the entire treatment with mycophenolate mofetil cinfa.
-For at least 6 weeks after stopping mycophenolate mofetil cinfa.
Consult your doctor to see which contraceptive method is most suitable for you. This will depend on your individual situation. It is recommended to use two contraceptive methods as this will reduce the risk of unintended pregnancy.
Consult your doctor as soon as possible if you believe your contraceptive method may not have been effective or if you have forgotten to take the contraceptive pill.
You are considered not susceptible to becoming pregnant if your case is one of the following:
Contraception in men taking mycophenolate mofetil cinfa
The available evidence does not indicate a higher risk of malformations or spontaneous abortion if the father takes mycophenolate. However, the risk cannot be completely ruled out. As a precaution, it is recommended that you or your female partner use a reliable contraceptive method during treatment and for at least 90 days after stopping mycophenolate mofetil. If you are planning to have a child, consult your doctor about the possible risks.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or believe you may be pregnant, consult your doctor or pharmacist before using this medication.Your doctor will discuss the risks and alternative treatment options with you if:
If you become pregnant during treatment with mycophenolate, inform your doctor immediately. However, continue taking mycophenolate mofetil until you see your doctor.
Pregnancy
Mycophenolate causes a very high frequency of spontaneous abortions (50%) and severe damage to the unborn baby (23-27%). Among the malformations reported are ear, eye, facial (cleft lip and palate), finger development, heart, esophagus (tube connecting the throat to the stomach), kidney, and nervous system (e.g., spina bifida) abnormalities. Your baby may be affected by one or more of these.
If you are a woman who can become pregnant, you must have a negative pregnancy test result before starting treatment and follow the contraceptive advice provided by your doctor. Your doctor may request multiple pregnancy tests to ensure you are not pregnant before starting treatment.
Breastfeeding
Do not take mycophenolate mofetil if you are breastfeeding. This is because small amounts of the medication may pass into breast milk.
Driving and using machines
The influence of mycophenolate mofetil on your ability to drive and use machines is moderate. If you feel drowsy, drowsy, or confused, talk to your doctor or nurse and do not drive or use tools or machines until you feel better.
Mycophenolate mofetil cinfa contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of thismedication as indicated byyour doctor or pharmacist. In case of doubt, consult your doctoror pharmacist again.
Amount to take
The amount to take depends on the type of transplant you have. The recommended doses areshown below. Treatment will continue until it is necessary to prevent rejection of thetransplanted organ.
Liver transplant
Adults
Children (between 2 and 18 years)
Heart transplant
Adults
Children
Liver transplant
Adults
Children
Taking this medication
Swallow the tablets whole with a glass of water. Do not break or crush them.Do not take any broken tablet.
If you take more mycophenolate mofetil cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.Do this also if someone accidentally takes your medication. Bring the medication packaging with you.
If you forget to take mycophenolate mofetil cinfa
If you ever forget to take the medication, take it as soon as you remember. Then continuetaking it at the usual hours. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with mycophenolate mofetil cinfa
Do not stop taking this medication unless your doctor tells you to. If you interrupt the treatment, you mayincrease the risk of rejection of the transplanted organ.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Consult your doctor immediately if you notice any of the following serious side effects, as you may need urgent medical treatment:
Common problems
Some of the most common problems are diarrhea, decreased white blood cell or red blood cell count in the blood, infection, and vomiting.Your doctor will perform regular blood tests to monitor any changes in:
Side effects are more likely to occur in children than in adults. These include diarrhea, infections, decreased white blood cell and red blood cell count in the blood.
Combating infections
The treatment with mycophenolate mofetil reduces the body's defenses. This is to prevent transplant rejection.For this reason, the body cannot fight infections as effectively as normal. This means you may contract more infections than usual.This includes infections affecting the brain, skin, mouth, stomach, and intestines, lungs, and urinary system.
Skin and lymphatic cancer
Like what happens in patients taking this type of medicine (immunosuppressants), a very small number of patients treated with mycophenolate mofetil have developed lymphoid and skin cancer.
Unwanted general effects
You may experience general side effects that affect your entire body.These include severe allergic reactions (such as anaphylaxis, angioedema), fever, feeling extremely tired, difficulty sleeping, pains (such as stomach pain, chest pain, joint or muscle pain), headache, flu-like symptoms, and swelling.
Other side effects may be:
Skin problemssuch as:
Urinary problemssuch as:
Digestive system and mouth problemssuch as:
Nervous system problemssuch as:
Cardiac and vascular problemssuch as:
Pulmonary problemssuch as:
Other problemssuch as:
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions. Do not use this medication if you observe any visible signs of deterioration.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.
Composition of cinfa micophenolate mofetil
Appearance of the product and content of the container
micophenolate mofetil cinfa 250 mg is presented in the form of film-coated tablets, oval and violet in color.
It is presented in PVC+PCTFE+PE/Al blisters, containing 100 film-coated tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Industrial Park Areta
31620 Huarte (Navarra) - Spain
Responsible for manufacturing
Tecnimede-Sociedade Técnico-Medicinal, S.A.
Quinta da Cerca, Caixaria
2565-187 Dois Portos, Portugal
Last review date of this leaflet: January 2022
The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.